Meglumine antimoniate

ApprovedSmall molecule

UUniversity of Brasilia

Meglumine antimoniate is one of 41 small molecule programs targeting Leishmaniasis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeishmaniasisActive, not recruiting

Cutaneous LeishmaniasisActive, not recruiting

Visceral LeishmaniasisActive, not recruiting

LeishmaniasisPhase 2/Phase 3

Active, not recruiting

Cutaneous LeishmaniasisApproved

Active, not recruiting

Visceral LeishmaniasisApproved

Active, not recruiting

Competition

Competitive Landscape

56 competitors in Cutaneous Leishmaniasis

#DrugCompanyPhaseTrials

Abelcet

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Levaquin

Garamycin

Impavido

KKnight Therapeutics (USA) Inc

Phase 3

12 5

Meglumine antimoniate

UUniversity of Brasilia

Approved

14 6

Pentam

FFresenius Kabi Oncology Ltd.

Phase 3

2 7

Aldara

BBausch Health Americas, Inc.

Phase 3

1 8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 9

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 10

Cipro

Bayer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Cutaneous Leishmaniasis

NCT02530697

Q1 2029

Phase 3Not yet recruiting

Cutaneous Leishmaniasis

NCT06822478

Clinical

Trials by Indication[1]

Cutaneous Leishmaniasis14 trials

Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis

Completed·OOswaldo Cruz Foundation·Phase 2/3·NCT01301924·72 enrolled

Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL)

Completed·TTehran University of Medical Sciences·Phase 3·NCT04340128

Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate Versus Meglumine Antimoniate and Allopurinol

Completed·—·N/A·NCT00480883·400 enrolled

Show 11 more trials

Combination, Miltefosine Monotherapy for Cutaneous Leishmaniasis in New World

Completed·DDrugs for Neglected Diseases·Phase 3·NCT04515186·184 enrolled

Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia

Unknown status·CCentro Internacional de Entrenamiento e Investigaciones Médicas·Phase 3·NCT00487253·150 enrolled

Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis

Completed·HHospital Universitário Professor Edgard Santos·Phase 2·NCT03294161·50 enrolled

The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil

Active, not recruiting·UUniversity of Brasilia·Phase 2·NCT02530697·160 enrolled

Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients

Completed·UUniversity of Brasilia·Phase 4·NCT00818818·13 enrolled

Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis

Completed·UUniversity of Brasilia·Phase 4·NCT00317980·280 enrolled

High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus

Terminated·HHospital Universitário Professor Edgard Santos·Phase 3·NCT01953744·53 enrolled

Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis

Completed·HHospital Universitário Professor Edgard Santos·Phase 2·NCT00973128·40 enrolled

Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis II.

Not yet recruiting·UUniversidad de Antioquia·Phase 3·NCT06822478·96 enrolled

Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis

Terminated·FFundación Cardiovascular de Colombia·Phase 3·NCT00317629·178 enrolled

Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil)

Completed·HHospital Universitário Professor Edgard Santos·Phase 2·NCT00600548·180 enrolled

Visceral Leishmaniasis1 trial

Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children

Completed·UUniversity of Brasilia·Phase 4·NCT01032187·101 enrolled

Leishmaniasis1 trial

Low Antimonial Dosage in American Mucosal Leishmaniasis

Unknown status·OOswaldo Cruz Foundation·Phase 2/3·NCT01301937·76 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Meglumine antimoniate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Meglumine antimoniate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Meglumine antimoniate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Brasilia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Brasilia

Meglumine antimoniate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2029

Trials by Indication[1]

Cutaneous Leishmaniasis14 trials

Visceral Leishmaniasis1 trial

Leishmaniasis1 trial

References

Drug Info

Quick Facts

Related News